Hepion Pharmaceuticals Announces Pricing of Public Offering
February 16, 2021 06:45 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the...
Hepion Pharmaceuticals to Present at the H. C. Wainwright 21st Annual Global Investment Conference
September 04, 2019 08:30 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
Hepion Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements
September 03, 2019 16:30 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
Hepion Pharmaceuticals Announces Dosing of First HBV Patient in 28-Day Study of CRV431
August 14, 2019 08:30 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Aug. 14, 2019 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
Hepion Pharmaceuticals Welcomes Dr. Stephen Harrison to its Scientific Advisory Board
August 07, 2019 13:00 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
Hepion Pharmaceuticals Announces Research Partnership with Applied Pharmaceutical Innovation, Faculty of Pharmacy & Pharmaceutical Sciences at University of Alberta
July 31, 2019 09:20 ET
|
Hepion Pharmaceuticals, Inc.
- Accelerating NASH Research Programs - EDISON, N.J., July 31, 2019 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of...
Hepion Pharmaceuticals Receives FDA Authorization to Proceed with IND Opening Study of CRV431 for NASH
July 29, 2019 16:15 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., July 29, 2019 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
ContraVir Pharmaceuticals Announces Name Change to Hepion Pharmaceuticals, Inc.; Trading Symbol Change to “HEPA”
July 22, 2019 14:00 ET
|
ContraVir Pharmaceuticals Inc.
EDISON, N.J., July 22, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
ContraVir Pharmaceuticals Submits IND Application for CRV431 for NASH
June 27, 2019 08:00 ET
|
ContraVir Pharmaceuticals Inc.
EDISON, N.J., June 27, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
ContraVir Pharmaceuticals Receives Positive FDA Response to CRV431 Pre-IND Package for NASH
June 20, 2019 16:30 ET
|
ContraVir Pharmaceuticals Inc.
EDISON, N.J., June 20, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...